<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01145001</url>
  </required_header>
  <id_info>
    <org_study_id>020718574</org_study_id>
    <secondary_id>P50DA009241-17</secondary_id>
    <nct_id>NCT01145001</nct_id>
  </id_info>
  <brief_title>Enhancing a High School Based Smoking Cessation Program</brief_title>
  <official_title>Contingency Management for Smoking Cessation in Adolescent Smokers - Phase IV, Enhancing a High School Based Smoking Cessation Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the the efficacy of adjunctive nicotine replacement
      therapy when used in combination with the contingency management (CM) + cognitive behavioral
      therapy intervention. Subjects will be randomly assigned to receive either a nicotine
      transdermal patch or a placebo patch as well as being randomly assigned to receive either CM
      or no CM; all subjects will receive cognitive behavioral therapy. We hypothesize that that
      subjects receiving both active nicotine patch and CM will have higher rates of abstinence
      from tobacco than subjects in the other groups.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abstinence Rates at the End of Treatment</measure>
    <time_frame>6 weeks</time_frame>
    <description>Our primary outcome will be point prevalence abstinence at the end of the treatment period defined as any self-report of cigarette use during the seven days prior to the last appointment confirmed by urine analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Continuous Abstinence During Treatment</measure>
    <time_frame>6 weeks</time_frame>
    <description>We will also examine continuous abstinence during the six week treatment period by urine analysis each week.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>Active Nicotine Patch and Contingency Management</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this group will receive Contingency Management and active nicotine patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine Patch with no Contingency Management</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this group will receive active nicotine patch without contingency management for abstinence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo patch and Contingency Management</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this group will receive a placebo transdermal patch and contingency management</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Patch and no Contingency Management</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this group will receive a placebo patch and will not receive contingency management</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioural Therapy</intervention_name>
    <description>Weekly CBT for all subjects</description>
    <arm_group_label>Active Nicotine Patch and Contingency Management</arm_group_label>
    <arm_group_label>Nicotine Patch with no Contingency Management</arm_group_label>
    <arm_group_label>Placebo patch and Contingency Management</arm_group_label>
    <arm_group_label>Placebo Patch and no Contingency Management</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Contingency Management</intervention_name>
    <description>incentives given for abstinence based on urine analysis</description>
    <arm_group_label>Active Nicotine Patch and Contingency Management</arm_group_label>
    <arm_group_label>Placebo patch and Contingency Management</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Transdermal Patch</intervention_name>
    <description>14mg ir 21mg doses based on weight and #cigs/day</description>
    <arm_group_label>Active Nicotine Patch and Contingency Management</arm_group_label>
    <arm_group_label>Nicotine Patch with no Contingency Management</arm_group_label>
    <other_name>Habitrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High School aged

          -  Desire to quit smoking

          -  Smoking &gt;5 cigarettes per day

          -  Able to read and write in English

        Exclusion Criteria:

          -  Current dependence on other substances

          -  Medical conditions that would contraindicate the use of a nicotine patch
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suchitra Krishnan-Sarin, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CMHC</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2010</study_first_submitted>
  <study_first_submitted_qc>June 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2010</study_first_posted>
  <results_first_submitted>August 24, 2016</results_first_submitted>
  <results_first_submitted_qc>August 24, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 19, 2016</results_first_posted>
  <last_update_submitted>November 4, 2016</last_update_submitted>
  <last_update_submitted_qc>November 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>smoking</keyword>
  <keyword>adolescents</keyword>
  <keyword>contingency management</keyword>
  <keyword>nicotine replacement therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active Nicotine Patch and Contingency Management</title>
          <description>Subjects in this group will receive Contingency Management and active nicotine patch
Cognitive Behavioural Therapy: Weekly CBT for all subjects
Contingency Management: incentives given for abstinence based on urine analysis
Nicotine Transdermal Patch: 14mg ir 21mg doses based on weight and #cigs/day</description>
        </group>
        <group group_id="P2">
          <title>Nicotine Patch With no Contingency Management</title>
          <description>Subjects in this group will receive active nicotine patch without contingency management for abstinence
Cognitive Behavioural Therapy: Weekly CBT for all subjects
Nicotine Transdermal Patch: 14mg ir 21mg doses based on weight and #cigs/day</description>
        </group>
        <group group_id="P3">
          <title>Placebo Patch and Contingency Management</title>
          <description>Subjects in this group will receive a placebo transdermal patch and contingency management
Cognitive Behavioural Therapy: Weekly CBT for all subjects
Contingency Management: incentives given for abstinence based on urine analysis</description>
        </group>
        <group group_id="P4">
          <title>Placebo Patch and no Contingency Management</title>
          <description>Subjects in this group will receive a placebo patch and will not receive contingency management
Cognitive Behavioural Therapy: Weekly CBT for all subjects</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Nicotine Patch and Contingency Management</title>
          <description>Subjects in this group will receive Contingency Management and active nicotine patch
Cognitive Behavioural Therapy: Weekly CBT for all subjects
Contingency Management: incentives given for abstinence based on urine analysis
Nicotine Transdermal Patch: 14mg ir 21mg doses based on weight and #cigs/day</description>
        </group>
        <group group_id="B2">
          <title>Nicotine Patch With no Contingency Management</title>
          <description>Subjects in this group will receive active nicotine patch without contingency management for abstinence
Cognitive Behavioural Therapy: Weekly CBT for all subjects
Nicotine Transdermal Patch: 14mg ir 21mg doses based on weight and #cigs/day</description>
        </group>
        <group group_id="B3">
          <title>Placebo Patch and Contingency Management</title>
          <description>Subjects in this group will receive a placebo transdermal patch and contingency management
Cognitive Behavioural Therapy: Weekly CBT for all subjects
Contingency Management: incentives given for abstinence based on urine analysis</description>
        </group>
        <group group_id="B4">
          <title>Placebo Patch and no Contingency Management</title>
          <description>Subjects in this group will receive a placebo patch and will not receive contingency management
Cognitive Behavioural Therapy: Weekly CBT for all subjects</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="44"/>
            <count group_id="B4" value="37"/>
            <count group_id="B5" value="154"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="149"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.53" spread="1.276"/>
                    <measurement group_id="B2" value="16.62" spread="1.233"/>
                    <measurement group_id="B3" value="16.66" spread="1.01"/>
                    <measurement group_id="B4" value="16.30" spread="1.151"/>
                    <measurement group_id="B5" value="16.53" spread="1.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Abstinence Rates at the End of Treatment</title>
        <description>Our primary outcome will be point prevalence abstinence at the end of the treatment period defined as any self-report of cigarette use during the seven days prior to the last appointment confirmed by urine analysis.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Nicotine Patch and Contingency Management</title>
            <description>Subjects in this group will receive Contingency Management and active nicotine patch
Cognitive Behavioural Therapy: Weekly CBT for all subjects
Contingency Management: incentives given for abstinence based on urine analysis
Nicotine Transdermal Patch: 14mg ir 21mg doses based on weight and #cigs/day</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Patch With no Contingency Management</title>
            <description>Subjects in this group will receive active nicotine patch without contingency management for abstinence
Cognitive Behavioural Therapy: Weekly CBT for all subjects
Nicotine Transdermal Patch: 14mg ir 21mg doses based on weight and #cigs/day</description>
          </group>
          <group group_id="O3">
            <title>Placebo Patch and Contingency Management</title>
            <description>Subjects in this group will receive a placebo transdermal patch and contingency management
Cognitive Behavioural Therapy: Weekly CBT for all subjects
Contingency Management: incentives given for abstinence based on urine analysis</description>
          </group>
          <group group_id="O4">
            <title>Placebo Patch and no Contingency Management</title>
            <description>Subjects in this group will receive a placebo patch and will not receive contingency management
Cognitive Behavioural Therapy: Weekly CBT for all subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Abstinence Rates at the End of Treatment</title>
          <description>Our primary outcome will be point prevalence abstinence at the end of the treatment period defined as any self-report of cigarette use during the seven days prior to the last appointment confirmed by urine analysis.</description>
          <units>percentage of participants not smoking</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1"/>
                    <measurement group_id="O2" value="24.3"/>
                    <measurement group_id="O3" value="38.6"/>
                    <measurement group_id="O4" value="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Continuous Abstinence During Treatment</title>
        <description>We will also examine continuous abstinence during the six week treatment period by urine analysis each week.</description>
        <time_frame>6 weeks</time_frame>
        <population>this is the intent to treat group-all starters (not treatment completers)</population>
        <group_list>
          <group group_id="O1">
            <title>Active Nicotine Patch and Contingency Management</title>
            <description>Subjects in this group will receive Contingency Management and active nicotine patch
Cognitive Behavioural Therapy: Weekly CBT for all subjects
Contingency Management: incentives given for abstinence based on urine analysis
Nicotine Transdermal Patch: 14mg ir 21mg doses based on weight and #cigs/day</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Patch With no Contingency Management</title>
            <description>Subjects in this group will receive active nicotine patch without contingency management for abstinence
Cognitive Behavioural Therapy: Weekly CBT for all subjects
Nicotine Transdermal Patch: 14mg ir 21mg doses based on weight and #cigs/day</description>
          </group>
          <group group_id="O3">
            <title>Placebo Patch and Contingency Management</title>
            <description>Subjects in this group will receive a placebo transdermal patch and contingency management
Cognitive Behavioural Therapy: Weekly CBT for all subjects
Contingency Management: incentives given for abstinence based on urine analysis</description>
          </group>
          <group group_id="O4">
            <title>Placebo Patch and no Contingency Management</title>
            <description>Subjects in this group will receive a placebo patch and will not receive contingency management
Cognitive Behavioural Therapy: Weekly CBT for all subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Continuous Abstinence During Treatment</title>
          <description>We will also examine continuous abstinence during the six week treatment period by urine analysis each week.</description>
          <population>this is the intent to treat group-all starters (not treatment completers)</population>
          <units>consecutive days of abstinence</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" spread="14.1"/>
                    <measurement group_id="O2" value="26.6" spread="13.7"/>
                    <measurement group_id="O3" value="29" spread="14.7"/>
                    <measurement group_id="O4" value="30" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected at baseline through duration of treatment-6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active Nicotine Patch and Contingency Management</title>
          <description>Subjects in this group will receive Contingency Management and active nicotine patch
Cognitive Behavioural Therapy: Weekly CBT for all subjects
Contingency Management: incentives given for abstinence based on urine analysis
Nicotine Transdermal Patch: 14mg ir 21mg doses based on weight and #cigs/day</description>
        </group>
        <group group_id="E2">
          <title>Nicotine Patch With no Contingency Management</title>
          <description>Subjects in this group will receive active nicotine patch without contingency management for abstinence
Cognitive Behavioural Therapy: Weekly CBT for all subjects
Nicotine Transdermal Patch: 14mg ir 21mg doses based on weight and #cigs/day</description>
        </group>
        <group group_id="E3">
          <title>Placebo Patch and Contingency Management</title>
          <description>Subjects in this group will receive a placebo transdermal patch and contingency management
Cognitive Behavioural Therapy: Weekly CBT for all subjects
Contingency Management: incentives given for abstinence based on urine analysis</description>
        </group>
        <group group_id="E4">
          <title>Placebo Patch and no Contingency Management</title>
          <description>Subjects in this group will receive a placebo patch and will not receive contingency management
Cognitive Behavioural Therapy: Weekly CBT for all subjects</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Rapid Heartbeat</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Change in appetite</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Sleepiness</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>VIvid Dreams</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dana Cavallo, Assistant Professor</name_or_title>
      <organization>Yale University</organization>
      <phone>2039747607</phone>
      <email>dana.cavallo@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

